# Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

> **NCT06364423** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 132 (estimated)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell
- B-Lymphocytic Leukemia, Chronic
- B-Cell Chronic Lymphocytic Leukemia
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Leukemia, Acute Lymphoblastic
- Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** Autologous HuCD19 ( Anti-CD19)CAR T cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06364423
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-03
- **Primary completion:** 2029-07-01
- **Final completion:** 2030-07-01
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364423, "Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06364423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*